JPMorgan Chase & Co. Cuts Stock Position in Inhibrx, Inc. (NASDAQ:INBX)

JPMorgan Chase & Co. trimmed its position in shares of Inhibrx, Inc. (NASDAQ:INBX) by 88.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 5,135 shares of the company’s stock after selling 39,130 shares during the quarter. JPMorgan Chase & Co.’s holdings in Inhibrx were worth $80,000 as of its most recent filing with the SEC.

Insider Activity

In other Inhibrx news, Director Jon Faiz Kayyem bought 69,686 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the acquisition, the director now owns 51,093 shares of the company’s stock, valued at $727,053.39. The trade was a -374.80 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 22.20% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Stock Performance

Shares of NASDAQ INBX opened at $12.72 on Tuesday. Inhibrx, Inc. has a 1-year low of $10.80 and a 1-year high of $18.95. The stock’s 50-day moving average is $14.49 and its two-hundred day moving average is $14.64.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.